Clinical Trials Logo

Bites and Stings clinical trials

View clinical trials related to Bites and Stings.

Filter by:

NCT ID: NCT03066986 Active, not recruiting - Immunotherapy Clinical Trials

Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax)

Jumpvax
Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the potential use of delta-inulin as an adjuvant to facilitate the desired immune response to Jack Jumper Ant (JJA) venom with a lower dose of venom, thus reducing adverse reactions, venom requirements and costs of treatment. Specifically we aim to compare outcomes of in-hospital JJA sting challenges and JJA venom specific IgE, and IgG4 responses to semi-rush JJA VIT at maintenance doses of 25 and 50 mcg of JJA venom, with and without delta-inulin adjuvant.

NCT ID: NCT02503800 Completed - Mastocytosis Clinical Trials

The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy

Start date: August 2015
Phase:
Study type: Observational

The investigators wish to evaluate the association between tryptase values as well as c-Kit mutation and adverse effects in the course of immunotherapy. The investigators also intend to assess the effect of immunotherapy on tryptase levels.

NCT ID: NCT00685230 Completed - Clinical trials for Scorpion Sting Envenomation

Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients

Start date: May 2004
Phase: Phase 2/Phase 3
Study type: Interventional

There is no FDA approved therapy for the treatment of scorpion envenomation, Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from trivial to life threatening. Patients stung by Centruroides scorpions develop a clinical syndrome which may require sedation with benzodiazepines and observation for 6 to 28 hours of intensive care monitoring. A safe therapy is necessary to halt the progression of symptoms early in the clinical course while avoiding the clinical deterioration that can occur en route to a tertiary facility. Alacramyn® is anticipated to be safer and more effective than the present standard of care, midazolam, and faster-acting such that the need for transport of most rural patients will be eliminated and will reduce hospitalization time. The working hypotheses are as follows: 1. The investigational antivenom is safe as treatment of scorpion sting envenomation. 2. The investigational antivenom is effective as treatment of scorpion sting envenomation.

NCT ID: NCT00624078 Completed - Clinical trials for Scorpion Sting Envenomation

Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation

Start date: May 2005
Phase: Phase 2/Phase 3
Study type: Interventional

This treatment protocol will enable therapeutic use of Anascorp in the management of systemic manifestations of scorpion sting envenomation, in patients for whom antivenom would otherwise be unavailable. The working hypotheses are as follows: 1. The investigational antivenom is safe as treatment of scorpion sting envenomation. 2. The investigational antivenom is effective as treatment of scorpion sting envenomation.

NCT ID: NCT00435552 Completed - Clinical trials for Insect Bites and Stings

Ease-it Spray for the Treatment of Fire Ant Stings

Start date: February 2007
Phase: Phase 1
Study type: Interventional

The application of Ease-it Spray will alleviate pain secondary to fire ant stings more quickly than placebo.

NCT ID: NCT00114894 Completed - Bites and Stings Clinical Trials

Prevention of Jellyfish Stings

Start date: April 2004
Phase: Phase 3
Study type: Interventional

Jellyfish stings are a common occurrence among ocean-goers worldwide with an estimated 150 million envenomations annually. Fatalities and hospitalizations occur annually, particularly in the Indo-Pacific regions. A new topical jellyfish sting inhibitor based on the mucous coating of the clown fish prevents 85% of jellyfish stings in laboratory settings. The field effectiveness is unknown. This is a field test to determine the real world effectiveness.